K. Hu

发表

Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival.

H. Masoudi, R. Nicholson, S. Dunn, 2008, Cancer research.

The expression of activated Y-box binding protein-1 serine 102 mediates trastuzumab resistance in breast cancer cells by increasing CD44+ cells

A. Astanehe, S. Dunn, A. Fotovati, 2010, Oncogene.

Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy

T. Nielsen, W. Lam, M. Marra, 2007, Breast Cancer Research.

Diosgenin Modulates Vascular Smooth Muscle Cell Function by Regulating Cell Viability, Migration, and Calcium Homeostasis

Mitra Esfandiarei, A. Kariminia, C. van Breemen, 2011, Journal of Pharmacology and Experimental Therapeutics.

YB-1 evokes susceptibility to cancer through cytokinesis failure, mitotic dysfunction, and HER2 amplification

P. Hieter, I. Barrett, C. Maxwell, 2011, Oncogene.

Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells

S. Dunn, A. Fotovati, Jennifer H. Law, 2012, Breast Cancer Research.

Disulfiram, a drug widely used to control alcoholism, suppresses self-renewal of glioblastoma and overrides resistance to temozolomide

S. Yip, S. Dunn, A. Fotovati, 2012, Oncotarget.

High-Grade Gliomas

C. Q. Lee, David T. W. Jones, Michael D. Brooks, 2012, Oxford Medicine Online.

Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition

J. Keats, M. Pujana, C. Lázaro, 2013, Oncotarget.

Overcoming resistance to sonic hedgehog inhibition by targeting p90 ribosomal S6 kinase in pediatric medulloblastoma

C. Hawkins, S. Dunn, Michael D. Taylor, 2014, Pediatric blood & cancer.

Inhibition of RSK with the novel small-molecule inhibitor LJI308 overcomes chemoresistance by eliminating cancer stem cells

S. Dunn, A. Stratford, N. Firmino, 2015, Oncotarget.

Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas

T. Triche, D. Wai, S. Dunn, 2009, Molecular Cancer Therapeutics.

A knock-in mouse strain facilitates dynamic tracking and enrichment of MEIS1.

P. Hoodless, F. Kuchenbauer, R. Humphries, 2017, Blood advances.

PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL+ human leukemia

G. Morin, C. Eaves, Xiaoyan Jiang, 2018, Science Translational Medicine.

Targeting p90 Ribosomal S6 Kinase Eliminates Tumor‐Initiating Cells by Inactivating Y‐Box Binding Protein‐1 in Triple‐Negative Breast Cancers

A. Ashworth, C. Print, P. Watson, 2012, Stem cells.

Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance.

C. Eaves, Jing Wang, A. Astanehe, 2010, Cancer research.

The Phosphoinositide-Dependent Kinase-1 Inhibitor 2-Amino-N-[4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-acetamide (OSU-03012) Prevents Y-Box Binding Protein-1 from Inducing Epidermal Growth Factor Receptor

S. Dunn, M. Bally, P. Mertens, 2007, Molecular Pharmacology.

YB‐1 Transforms Human Mammary Epithelial Cells Through Chromatin Remodeling Leading to the Development of Basal‐Like Breast Cancer

G. Mills, C. Maxwell, A. Astanehe, 2014, Stem cells.

Targeting YB-1 in HER-2 overexpressing breast cancer cells induces apoptosis via the mTOR/STAT3 pathway and suppresses tumor growth in mice.

C. Eaves, M. Hung, A. Astanehe, 2008, Cancer research.

Suppresses Tumor Growth in Mice Cells Induces Apoptosis via the mTOR / STAT 3 Pathway and Targeting YB-1 in HER-2 Overexpressing Breast Cancer

C. Eaves, M. Hung, A. Astanehe, 2008 .

Response to Comment on “PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL+ human leukemia”

G. Morin, C. Eaves, Xiaoyan Jiang, 2019, Science Translational Medicine.

Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy.

T. Nielsen, W. Lam, M. Marra, 2007, Breast cancer research : BCR.

High grade gliomas

C. Q. Lee, David T. W. Jones, Michael D. Brooks, 2022, Progress in Brain Research.

Inhibition of RSK with the novel small-molecule inhibitor LJI308 overcomes chemoresistance by eliminating cancer stem cells

S. Dunn, A. Stratford, K. Hu, 2015, Oncotarget.